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ARTICLE
Seemingly Neutral Polymorphic Variants May Confer Immunity
to Splicing-Inactivating Mutations: A Synonymous SNP in Exon 5
of MCAD Protects from Deleterious Mutations in a Flanking
Exonic Splicing Enhancer
Karsten Bork Nielsen, Suzette Sørensen, Luca Cartegni, Thomas Juhl Corydon,
Thomas Koed Doktor, Lisbeth Dahl Schroeder, Line Sinnathamby Reinert, Orly Elpeleg,
Adrian R. Krainer, Niels Gregersen, Jørgen Kjems, and Brage Storstein Andresen
The idea that point mutations in exons may affect splicing is intriguing and adds an additional layer of complexity when
evaluating their possible effects. Even in the best-studied examples, the molecular mechanisms are not fully understood.
Here, we use patient cells, model minigenes, and in vitro assays to show that a missense mutation in exon 5 of the
medium-chain acyl-CoA dehydrogenase (MCAD) gene primarily causes exon skipping by inactivating a crucial exonic
splicing enhancer (ESE), thus leading to loss of a functional protein and to MCAD deﬁciency. This ESE functions by
antagonizing a juxtaposed exonic splicing silencer (ESS) and is necessary to deﬁne a suboptimal 3′ splice site. Remarkably,
a synonymous polymorphic variation in MCAD exon 5 inactivates the ESS, and, although this has no effect on splicing
by itself, it makes splicing immune to deleterious mutations in the ESE. Furthermore, the region of MCAD exon 5 that
harbors these elements is nearly identical to the exon 7 region of the survival of motor neuron (SMN) genes that contains
the deleterious silent mutation in SMN2, indicating a very similar and ﬁnely tuned interplay between regulatory elements
in these two genes. Our ﬁndings illustrate a mechanism for dramatic context-dependent effects of single-nucleotide
polymorphisms on gene-expression regulation and show that it is essential that potential deleterious effects of mutations
on splicing be evaluated in the context of the relevant haplotype.
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In recent years, it has become increasingly clear that ex-
onic point mutations located outside the splice sites may
affect pre-mRNA splicing and thereby cause disease.1,2Cor-
rect pre-mRNA splicing not only requires that the splice-
site sequences3 be present at the exon-intron borders
but is also critically dependent on additional intronic and
exonic regulatory sequences. Exonic splicing enhancers
(ESEs) and exonic splicing silencers (ESSs) bind splicing
factors to either positively or negatively affect recognition
of nearby splice sites. Consequently, mutations located in
ESE or ESS elements may affect splicing, and a signiﬁcant
proportion of exonic point mutations may therefore have
a completely different effect from what can be predicted
from the genetic code. The signiﬁcance and prevalence of
this phenomenon may have been dramatically underes-
timated, since most studies of disease genes are limited to
analysis of genomic DNA. Studies at the mRNA level are
rarely performed and are usually considered only when
the effect of the mutation on the encoded protein clearly
does not explain the disease phenotype, as in synonymous
variations. Recently, the possible role of ESEs and ESSs in
human disease genes has received more attention; con-
sequently, the number of known examples in which mu-
tations that affect such elements cause disease have in-
creased dramatically.1,2 Moreover, accumulating evidence
indicates that conservation of ESE elements may play a
role in evolution by restricting the evolvement of syn-
onymous substitutions in homologous genes.4–6
Because of this emerging picture of a more important
role for ESE and ESS elements in gene function, multiple
search algorithms for potential ESE and ESS motifs have
been developed7–10 and are now widely used for evaluation
of sequence variations in disease genes.11–13 Because the
recognition sequences for the splicing factors that bind to
ESE and ESS elements are degenerate and overlapping,1
and because splicing of an exon is often determined by a
ﬁnely tuned and complex interplay between more than
one regulatory element, these in silico predictions are still
rather imprecise, and there is no doubt that only a fraction
of the predicted motifs are crucial determinants for correct
splicing.14 It is therefore important that predictions are
cautiously interpreted and followed up by functional char-
acterization, to avoid misinterpretations and to gain more
knowledge about these elements and their interplay.
The number of disease-associated exonic mutations for
which possible effects on splicing have been investigated
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by functional experiments is, however, still limited, and
even the most extensively investigated examples are not
yet fully understood. For instance, in spinal muscular at-
rophy (types I, II, and III [MIM 253300, 253550, and
253400, respectively]), the survival of motor neuron 2
(SMN2) gene (Entrez Gene accession number 6607) cannot
efﬁciently compensate for inactivation of the survival of
motor neuron 1 (SMN1) gene (Entrez Gene accessionnum-
ber 6606), because a silent 6CrT substitution in SMN2
exon 7 causes exon skipping.15,16 Different models have
attempted to explain the effect of the6CrT substitution
as either the loss of an ESE that binds the splicing factor
SF2/ASF (“ESE-loss model”)17 or the creation of an ESS that
binds the hnRNP A1/A2 splicing-inhibitory proteins (“ESS-
gain model”).18 Recently, it was substantiated that inefﬁ-
cient splicing of SMN2 is indeed due to the loss of an SF2/
ASF–dependent ESE and not to the creation of an ESS and
that hnRNP A1/A2 plays an important role as a general
inhibitor of both SMN1 and SMN2 exon 7 splicing.19 In
addition, there are also other important splicing regula-
tory elements in SMN1 and SMN2 exon 720,21 and in the
ﬂanking introns.22,23 Despite the intense focus on eluci-
dation of SMN exon 7 splicing regulation by numerous
laboratories, the interplay of all positive and negative el-
ements is still not fully understood.
Medium-chain acyl-CoA dehydrogenase (MCAD) deﬁ-
ciency (MIM 201450) is the most common defect of the
mitochondrial b-oxidation of fatty acids in humans. Most
newborn-screening programs now include screening for
MCAD deﬁciency by use of tandem mass spectrometry
(MS/MS) analysis for diagnostic metabolites.24–26 Because
a diagnosis can be completed by identiﬁcation of delete-
rious mutations in the MCAD gene (Entrez Gene accession
number 34), it is important that the consequences of all
identiﬁed mutations can be correctly assessed.
In the present study, we use patient cells, minigenes,
and in vitro techniques to demonstrate that the conse-
quences of two point mutations in MCAD exon 5, a
c.351A/C (T92T) synonymous polymorphic variation and
a c.362CrT (T96I) disease-associated missense mutation,
are entirely different from what was initially suggested.24
We show that, despite their location away from the splice
sites, both mutations affect critical splicing regulatory el-
ements, with opposite effects on splicing. Interestingly,
the region of exon 5 that contains these two mutations
is nearly identical to the region of SMN1/2 exon 7 that
harbors the causative silent 6CrT substitution and the
associated regulatory elements. We investigate the molec-
ular basis for MCAD exon 5 splicing regulation, and we
propose an explanatory model, which also contributes to
a better understanding of splicing regulation of SMN1/2
exon 7 and other disease genes.
Material and Methods
Patients
Cells from two patients with enzymatically conﬁrmed MCAD de-
ﬁciency were studied. Patient 1 is a girl who presented with clin-
ical symptoms at age 10 mo and at age 9 years. Sequence analysis
of the entire MCAD gene from patient 1, as well as of exons 5
and 11 from her parents, showed that the index patient is com-
pound heterozygous for the c.362CrT mutation in exon 5 and
for the prevalent c.985ArG mutation in exon 11. Both parents
were carriers for one of the mutations. Patient 2 is a girl who
presented clinically at age 10 mo. Sequence analysis of the index
patient and her parents showed that she is homozygous for the
c.362CrT mutation in exon 5 and that both parents are carriers.
In addition to these two patients, we have identiﬁed three un-
related newborns with the c.362CrT mutation (one baby with a
genotype identical to that of patient 1,24 one with a genotype
identical to that of patient 2, and one with the c.362CrT mu-
tation in one allele and a 13-bp insertion mutation in the other
allele) (B. S. Andresen, unpublished data) among babies with an
acyl-carnitine proﬁle indicative of MCAD deﬁciency who have
been identiﬁed in MS/MS–based newborn-screening programs in
the United States and Denmark. In all ﬁve patients, PCR ampli-
ﬁcation and sequence analysis of all exons, including part of the
ﬂanking intron sequences, of the human MCAD gene, were per-
formed as described elsewhere.27 Relevant informed consent
forms have been obtained.
MCAD minigene.—A 2,274-bp fragment of the human MCAD
gene,28 encompassing position 3 in exon 3, intron 3, exon 4,
intron 4, exon 5, intron 5, and position 53 in exon 6, was am-
pliﬁed by PCR with the use of Pfu polymerase and primers
MCSPL1S (5′-GGGAATTCGGTACCGGAGCCAACATGGTCACC-
GAACAGCAGAAAGAATTTCAAGC-3′) and MCSPL1AS (5′-CCCC-
CGCTCGAGTTACTATTAATTACACATCAATGGCTCCTCAGTCA-
TTCACCCCAA-3′), which introduced restriction sites for KpnI
and XhoI. The MCSPL1S primer matches the nucleotides from
cDNA positions 122–149 in exon 3 and introduces an inframe
ATG start codon followed by a valine codon in front of the codon
for threonine at cDNA positions 124–126. The MCSPL1AS primer
matches the nucleotides corresponding to MCAD cDNA positions
436–468 and introduces a TGA stop codon by replacing G at
position 442 with a T. In addition, an inframe aspargine codon
and three inframe stop codons are added to the sequence after
position 468. A human BAC DNA (GenBank accession number
AL592082) obtained from the Sanger Centre (Oxford, United
Kingdom) was used as template for PCR. The PCR product was
digested with KpnI and XhoI and was cloned into the polylinker
of the pcDNA3.1 vector (Invitrogen). The insert was sequenced
to ensure that no PCR-derived errors were present. All mutations
were introduced by PCR-based mutagenesis with the use of Pfu
polymerase.
Very-long-chain acyl-CoA dehydrogenase (VLCAD) minigene.—A
fragment of the human VLCAD gene (Entrez Gene accession
number 37), spanning from the position in exon 11 that corre-
sponds to cDNA position 1078 to the position in exon 14 that
corresponds to cDNA position 1422, was ampliﬁed by PCR with
the use of Pfu polymerase, control human genomic DNA, and
primers Vl1114s (5′-GGGCGGAATTCGGAGATGGTAGATCAGG-
CCACTAATCGTACCCAGT-3′) and vl714as1 (5′-CGGGGTGAGC-
TCGGGAGTATTCACAGCCACAAACAGCCGAAGAATGTC-3′).
The primers introduce restriction sites for SacI and EcoRI and add
an inframe ATG start codon immediately upstream of the nucle-
otide corresponding to cDNA position 1078 and a TGA stop co-
don immediately downstream of position 1422. This PCRproduct
was inserted between the SmaI and EcoRI sites in the polylinker
of the pciNeo (Promega) vector. The insert was sequenced to en-
sure that no PCR-derived errors were present. The resulting vector
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was digested with EcoRI and NotI, and the VLCAD gene fragment
was cloned into the polylinker of the pcDNA3.1 vector (Invi-
trogen). Exon 5 and part of the ﬂanking introns were ampliﬁed
with primers MCEX5BLPS (5′-GGTCATATGCTCAGCAATTAAAA-
TAGTTTACC-3′) and MCEX5BLPAS (5′-TCTTGTGCTGAGCTTTA-
AAGAAAACTGTGTGTACC-3′), with the use of Pfu polymerase
and either the wild-type or the c.362CrT mutant MCAD mini-
gene plasmids as templates. The PCR products were digested with
BlpI and were used to replace a fragment spanning from the BlpI
site in intron 11 to the BlpI site in intron 12 of the VLCAD gene.
In this way, the last 80 nt of MCAD intron 4, the entire exon 5
(with either wild type or c.362CrT), and the ﬁrst 145 nt of intron
5 replaced a fragment harboring the last 264 nt of intron 11, exon
12, and the ﬁrst 46 nt of intron 12 in the VLCAD minigene.
BRCA1 minigene.—A fragment spanning the last 86 bp of intron
17, exon 18 (78 bp), and the ﬁrst 184 bp of intron 18 of the
human BRCA1 gene (Entrez Gene accession number 672)was PCR
ampliﬁed from control human genomic DNA with the use of Pfu
polymerase and primers BRCA-1S (5′-GGGAGTGTGCTAAGCTG-
AGGCTCTTTAGCTTCTT-3′) and BRCA-1AS (5′-CCCAGCATCAC-
CAGCTTAGCTGAACAAAGTGAT-3′), were cloned into the PCR-
Script AmpSK vector, were sequenced, and were subcloned into
the pSPL3 exon-trapping vector (Invitrogen) with the use of the
NotI and BamHI restriction sites. By use of PCR-based mutagen-
esis, four constructs were made: BRCA1 wild-type (BRCA1-WT),
which has a sequence identical to human BRCA1 gene position
64700–65025 (GenBank accession number L78833); BRCA1-
NL,29,30 which harbors a GrT mutation at position 6 in exon 18;
BRCA1-MCAD 362C, in which the BRCA1 exon 18 ESE motif at
positions 6–12 (CTGAGTT) was replaced by the putative MCAD
exon 5 ESE CAGACTG (C corresponding to MCAD 362C is un-
derlined); and BRCA1-MCAD 362T, in which the putative BRCA1
exon 18 ESE motif CTGAGTT is replaced by the mutated MCAD
exon 5 ESE CAGATTG (T corresponding to MCAD 362T is
underlined).
pSXN minigene.—We used a version of the pSXN minigene re-
porter31 lacking the natural globin translation–initiation codon,
to avoid the potential inﬂuence of nonsense-mediated mRNA
decay (NMD).32 Mutant constructs were obtained by ligating dou-
ble-stranded oligonucleotides with the desired sequencesbetween
the SalI and BamHI sites in exon 2. All minigene vectors were
sequenced to ensure that no PCR-derived errors were introduced.
Transient transfection experiments were conducted on all cell
types with the use of FuGENE 6 Transfection Reagent (Roche
Molecular Biochemicals). All transfection experiments were per-
formed in duplicate or triplicate and in at least two independent
transfections. COS-7, Chang (human liver epithelia cells), and
HEK-293 cells were grown in RPMI 1640 glutamine with 5%–
10% (v/v) fetal calf serum. N2A and NT2 cells were grown in
Dulbecco’s modiﬁed Eagle medium with 10% (v/v) fetal calf se-
rum. Cells were harvested 48 h posttransfection. Cotransfections
with the expression vectors for SF2/ASF, SC35, SRp40, SRp55,9G8,
or hTra2-b1 were performed using 0.5 mg of the relevant expres-
sion vector or of the empty expression vectors pCG or pCINeo
(Promega). Transfection efﬁciency was evaluated by cotransfec-
tion of a green ﬂuorescent protein–expressing plasmid.
RNA interference.—For RNA interference, RNA oligonucleotides
identical to those used by Kashima and Manley18 and by Cartegni
and coworkers19 were purchased from DNA Technology: hnRNP
A1-S (5′-CAGCUGAGGAAGCUCUUCAUU-3′), hnRNP A2-S (5′-
GGAACAGUUCCGUAAGCUCUU-3′), and a negative control (5′-
UAGCGACUAAACACAUCAA-3′). Approximately 75,000 HEK-
293 cells cultivated in 24-cell plates were transfectedwith 50pmol
of the double-stranded hnRNP A1 and hnRNP A2 RNA oligo-
nucleotides or the negative control RNA with Dharmafect 1 trans-
fection reagent (Dharmacon). The cells were transfected with 85
ng of the various MCAD minigenes 24 h later with FuGene 6
transfection reagent (Roche Molecular Biochemicals). Cells were
harvested 72 h after the initial transfection. hnRNP A1 down-
regulation was monitored by western blotting with the use of an
afﬁnity-puriﬁed hnRNP A1 goat polyclonal antibody (N-15) and
an afﬁnity-puriﬁed hnRNP A2/B1 goat polyclonal antibody (Santa
Cruz Biotechnology). Extraction of total RNA from cultured ﬁ-
broblasts or from transfected Chang, HEK-293, COS-7, N2A, or
NT2 cells was performed using an RNAzol kit (WAK-Chemie).
After DNaseI treatment, ﬁrst-strand cDNA synthesis was per-
formed from total RNA with the use of a ﬁrst-strand cDNA-syn-
thesis kit (Clontech).
Splicing from the minigenes was examined by PCR of cDNA
prepared from the transfected cells. We employed minigene-spe-
ciﬁc primers to exclude detection of the endogenous MCAD or
VLCAD gene. For ampliﬁcation of cDNA prepared from cells
transfected with the MCAD minigene, the VLCAD minigene, the
BRCA1 minigene, or the pSXN minigene, the following primers
were used: MCAD 242S (5′-CCTGGGAACTTGGTTTAATG-3′)
and MCTEST2AS (5′-AGACTCGAGTTACTATTAATTACACATC-
3′), VLCAD HVL1114test (5′-GAATTCGGAGATGGTAGATCAG-
3′) and HVL1310AS (5′-CCATGATTTGGATGCATTCATCTGTC-
3′), BRCA1 SA2 (5′-TCTGAGTCACCTGGACAACC-3′) and SD6
(5′-ATCTCAGTGGTATTTGTGAGC-3′), and pSXN pSXN13s (5′-
AAGTTGGTGGTGAGGCCCTGGGCAG-3′) and pSXN13as (5′-
CCCACGTGCAGCCTTTGACCTAGTA-3′).
Quantitation of mRNA with Use of TaqMan Assays
The amounts of MCAD mRNA were estimated relative to b-actin
mRNA by quantitative PCR analysis, as described elsewhere.33 As
described above, 1 mg of DNaseI-treated total RNA isolated from
ﬁbroblast cells was used for cDNA synthesis. For relative quan-
tiﬁcation of ﬁbroblast MCAD mRNA, 10-fold dilution series of the
cDNA samples from the four control ﬁbroblast cells were mea-
sured on the instrument, to generate standard curves. The cDNA
samples were ampliﬁed as recommended by the manufacturer
with the use of TaqMan Universal PCR Master Mix (number
AmpErase UNG), Assay-on-Demand TaqMan assay for human
b-actin (Applied Biosystems [assay identiﬁcation number
Hs99999903_m1]), andAssay-by-Design TaqMan assay for thehu-
man MCAD mRNA (Applied Biosystems [assay identiﬁcation
number Hs00163494_m1]). The sense primer used in the MCAD
assay is located at the exon 1/exon 2 junction of theMCAD gene.28
The probes for all assays are labeled with FAM reporter dye at the
5′ end. For each measurement, the PCR was performed in trip-
licate wells under standard conditions with use of an ABI Prism
7000 Sequence Detection System (Applied Biosystems). Final
quantitation was done using the standard curve method (ABI
7000 software). The relative MCAD mRNA amounts were calcu-
lated by dividing the mRNA amounts by the b-actin mRNA
amounts.
Plasmid Templates for In Vitro Transcription of MCAD
Exon 5
Primers MCE5KpnI-S (5′-GGCGGAGGTACCGGTCTTGGACTTG-
GAACTTTTGAG-3′) andMCE5HindIIIAS (5′-GCGCGCGAAGCTT-
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CCCCAAAGAATTTCCTTCAAT-3′) were used to amplify a region
of exon 5 corresponding to c.289–c.387 with the use of MCAD
minigenes, with the relevant variations at cDNA positions c.351
and c.362 as templates. PCR products were cloned between the
KpnI and HindIII sites in the pGEM-3Zf vector (Promega).
The resulting vectors (pGEM351C362C, pGEM351A362C,
pGEM351C362T, pGEM351A362T, pGEM351ASMN1, and
pGEM351ASMN2) were all sequenced to exclude PCR-derived er-
rors before they were used as templates for in vitro transcription.
Immobilization of RNA on Agarose Beads and Binding
Assays
Substrate RNA for binding to agarose beads was synthesized by
in vitro transcription with T7 RNA polymerase from plasmid tem-
plates pGEM351C362C, pGEM351A362C, pGEM351C362T, and
pGEM351A362T, linearized with HindIII. Final nucleotide con-
centrations in transcription reactions were 0.6 mM rATP, 0.6 mM
rCTP, 0.6 mM rGTP, and 0.6 mM UTP. The coupling of RNA to
adipic acid dihydrazide agarose beads was done according to a
published procedure.35 Binding assays were subsequently per-
formed using a modiﬁcation of a published procedure.35 The im-
mobilized RNA was added to a 650-ml splicing reaction containing
250 ml HeLa nuclear extract, 1 mM ATP, 5 mM creatine phosphate,
2.5 mM MgCl2, 0.25 mg/ml tRNA, 0.5% Triton-X-100, and 97.5 ml
buffer D (20 mM HEPES-KOH [pH 7.6], 5% glycerol, 100 mM KCl,
0.2 mM EDTA, and 0.5 mM dithiothreitol [DTT]) and was incu-
bated for 20 min at 30C. After incubation, the beads werewashed
four times in 1 ml buffer D containing 4 mM MgCl2 and 0.5%
Triton-X-100. Finally, the proteins bound to the RNA were eluted
by the addition of protein sample buffer and were heated for 5
min at 90C. The proteins were separated on a 12% SDS-polyacryl-
amide gel, were electroblotted onto a nitrocellulose membrane,
and were probed with the hnRNP A1 antibody mAb 4B1036 or a
monoclonal mouse SF2/ASF antibody (AK96 from Zymed Labo-
ratories [Invitrogen]).
RNA Oligonucleotide-Afﬁnity Chromatography
High-performance liquid chromatography–puriﬁed RNA (O-Silyl)
oligonucleotides with 3′-biotin were purchased from DNA Tech-
nology. Six different oligonucleotides were used: MCAD351A-bio
corresponding to positions c.341–360 (5′-ATGGATGTACAGGGG-
TTCAG-biotin), MCAD351C-bio corresponding to positions
c.341–360 (5′-ATGGATGTACCGGGGTTCAG-biotin),MCAD362C-
bio corresponding to positions c.353–372 (5′-GGGTTCAGACTG-
CTATTGAA-biotin), MCAD362T-bio corresponding to positions
c.353–372 (5′-GGGTTCAGATTGCTATTGAA-biotin), SMN1-bio
(5′-GGGTTCAGACAAAATCAAAA-biotin), and SMN2-bio (5′-
GGGTTTAGACAAAATCAAAA-biotin). For each puriﬁcation, 100
pmol of RNA oligonucleotide was coupled to 100 ml of strepta-
vidin-coupled magnetic beads (Dynal) for 15 min in 1# binding
buffer (20 mM Hepes/KOH [pH 7.9], 72 mM KCl, 1.5 mM MgCl,
1.56 mM MgAc, 0.5 mM DTT, 4 mM glycerol, 0.75 mM ATP, and
0.2 mg/ml bulk tRNA). The suspension was then placed in the
magnet, and the supernatant was removed. The oligonucleotide-
bead complexes were then resuspended in 500 ml of bindingbuffer
containing 100 ml of HeLa nuclear extract (Cilbiotech) and were
incubated for 25 min at room temperature. Then, the supernatant
was removed, and the beads were washed three times in binding
buffer containing 300 mM KCl. Finally, the proteins bound to
the RNA were eluted by the addition of 50 ml protein sample buffer
heated for 4 min at 90C, the biotinylated RNA oligonucleotides
were immobilized in a magnet, and 12.5 ml of the supernatant
proteins were separated on a 4%–12% SDS-polyacrylamide gel
and were electroblotted onto a nitrocellulose membrane. The
membranes were then probed with an afﬁnity-puriﬁed hnRNP
A1 goat polyclonal antibody (N-15) (Santa Cruz Biotechnology)
or a monoclonal mouse SF2/ASF antibody (AK96 from Zymed
Laboratories [Invitrogen]).
Results
The c.362CrT Mutation Causes Exon 5 Skipping and
Decreased Levels of MCAD mRNA in Patient Cells
We initially reported the c.362CrT mutation in a baby
identiﬁed in a U.S. MS/MS newborn-screening program
and demonstrated that the encoded T96I mutant MCAD
protein had a low but detectable level of enzyme activity.24
Since then, we have identiﬁed the c.362CrT mutation in
two additional newborns and in three patients with clin-
ically manifested disease. When we analyzed ﬁbroblast
cDNAs from the two patients, we found that the c.362CrT
mutation leads to severely reduced MCAD mRNA levels
(ﬁg. 1A and 1B). Further analysis showed that mRNA from
alleles with c.362CrT displays a high level of exon 5 skip-
ping (ﬁg. 1C). Exon 5 skipping leads to a shifted reading
frame, resulting in a premature termination codon in exon
6, indicating that the decreased amount of MCAD mRNA
from the c.362CrT allele is a result of NMD.1
The MCAD c.362CrT Mutation Disrupts an ESE
To investigate why this mutation is associated with exon
5 skipping, we constructed an MCAD minigene (ﬁg. 2A),
introduced the c.362CrT mutation, and transfectedChang
cells. This showed that the c.362CrT mutation by itself
is sufﬁcient to cause skipping of exon 5 (ﬁg. 2A). To in-
vestigate whether the sequences of the neighboring exons
and introns are involved in mediating the exon 5 skipping
effect, we cloned exon 5 and part of the ﬂanking introns
into a VLCAD minigene. Transfection of Chang cells
showed that the c.362CrT mutation causes exon 5 skip-
ping in this context also (ﬁg. 2B), and, thus, sequences
present in the subcloned part of MCAD are sufﬁcient to
reproduce this phenomenon. Examination of the splice-
site consensus sequences ﬂanking exon 5 showed that the
intron 4 3′ splice site conforms poorly to the consensus
sequence (ﬁg. 2A). Therefore, we hypothesized that the
c.362CrT mutation might interfere with splicing regula-
tory elements in exon 5 that are necessary for this weak
3′ splice site to be recognized. To test this hypothesis, we
generated minigene constructs in which the upstream 3′
splice site was converted to a strong splice site and other
constructs in which we deleted either 3 bp or 9 bp sur-
rounding position c.362 (ﬁg. 2A). Both deletions caused
complete exon 5 skipping when introduced into the con-
struct with the wild-type 3′ splice site. Introduction of a
strong 3′ splice site normalized splicing from allminigenes
(ﬁg. 2A). These results suggest that exon 5 skipping is due
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Figure 1. Analysis of MCAD cDNA from patient ﬁbroblasts. A, We used a LightCycler-based assay for the c.985ArG mutation,24 to
analyze two samples of cDNA from cultured ﬁbroblasts from patient 1 and from four other individuals heterozygous for the c.985ArG
mutation. In patient 1, the height of the peak resulting from the allele without the c.985ArG mutation (i.e., the allele with the
c.362CrT mutation) was reduced compared with the peak from the allele with the c.985ArG mutation. When four other individuals
heterozygous for the c.985ArG mutation were analyzed, the two peaks were of comparable size. This indicates that MCAD mRNA from
the allele with the c.362CrT mutation is present in lower amounts than MCAD mRNA from the other MCAD allele. B, Quantitative PCR
analysis of the relative amounts of MCAD cDNA relative to b-actin cDNA.33 Analysis of cDNA prepared from ﬁbroblasts from patient (Pat)
2, who is homozygous for the c.362CrT mutation, showed that MCAD mRNA from the allele with the c.362CrT mutation results in only
∼20% of that in controls (Cont). Patient E, described elsewhere, is homozygous for a 2-bp deletion in exon 11, corresponding to cDNA
positions 955–956, that leads to severely decreased amounts of MCAD mRNA.27,33 The mean of the four control ﬁbroblasts (controls A–
D) was assigned the value 100%, and the error bars indicate the range ( ). C, Ampliﬁcation of cDNA from patients 1 and 2 andnp 3
from three controls with primers located in exons 4 and 6 demonstrated that mRNA from alleles with the c.362CrT mutation display
a high level of exon 5 skipping. When the bands were excised and sequenced separately, results showed that the normal-sized band
from patient 1 had a wild-type sequence at position c.362, whereas the shorter band from the two patients was missing exon 5.
to inactivation of an ESE that comprises position c.362
and that this ESE is needed only because of the weak 3′
splice site of intron 4. These results also strongly support
the notion that the observation of decreased levels of
c.362CrT mutant MCAD mRNA in patient cells is indeed
a result of exon skipping and is not caused by instability
of the c.362CrT mutant mRNA.
We used sequence matrices for scoring potential ESE
motifs7–9 to search MCAD exon 5 in the region surround-
ing the c.362CrT mutation. No ESE comprising position
c.362 was identiﬁed by the RESCUE-ESE program or the
PESX program, whereas the ESEﬁnder 2.0 program showed
that position c.362 is located within overlapping high-
score motifs for three serine/arginine–rich (SR) proteins—
namely, SF2/ASF, SRp40, and SC35—and that c.362CrT
abrogates the high-score motifs for SF2/ASF and SRp40
(ﬁg. 3A). The sequence of the MCAD SF2/ASF high-score
heptamer is similar to the SF2/ASF high-score heptamer
in SMN1 that is disrupted by the 6CrT substitution in
SMN2.17 The SMN2 heptamer can achieve ESE activity
comparable to the SMN1 heptamer if the SF2/ASF high-
score motif is reestablished by introduction of a second-
site suppressor mutation (11TrG).17 To explore this sim-
ilarity between the high-score heptamers in MCAD and
SMN1, we introduced a c.363TrG mutation, which is
equivalent to SMN2 11TrG, into the wild-type and
c.362CrT mutant MCAD constructs. This mutation rees-
tablished the high-score motif for SF2/ASF in the double
mutant and improved the score of the existing SF2/ASF
motif in the wild-type context (ﬁg. 3A). On the other
hand, the same mutation eliminates the SRp40 high-score
motif in the wild-type context and does not reconstitute
it in the double mutant, whereas the SC35 high-score mo-
tif is reduced in both cases. Just as was previously observed
for the 11TrG suppressor mutation in the SMN2 hepta-
mer, c.363TrG neutralized the negative effect of c.362CrT
(ﬁg. 3B). In addition, exon 5 inclusionwas improvedwhen
c.363TrG was introduced in the wild-type minigene,
again correlating with the SF2/ASF motif.
Together, these ﬁndings indicate that splicing of MCAD
exon 5, similar to SMN1 exon 7, is dependent on the pres-
ence of an ESE with a high-score SF2/ASF motif and that
the MCAD ESE and the SMN1 ESE are probably function-
ally similar. Therefore, we substituted the MCAD ESE in
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Figure 2. Minigene analysis. A, Schematic representation showing the MCAD minigene. The variants in which the weak intron 4 3′
splice site was optimized by substitution to pyrimidines at positions 15(c), 10(c), 9(t), and 7(t) were named “IVS.” Part of
the sequence at the intron 4–exon 5 splice site of the IVS and wild-type (Wt) versions, as well as the corresponding consensus sequence
(Cons), is displayed. Analysis by the Splice Site Prediction by Neural Network program (Fruitﬂy) gives a score of only 0.12 for the
suboptimal intron 4 3’ splice site, whereas the optimized sequence gives a score of 1.0. Also, the positions of the Del3, Del9, and
c.362CrT mutations in the MCAD sequence (positions c.351–c.371) are shown. Nearly identical results were observed when we transfected
other types of cells (i.e., HEK-293, COS-7, N2A, and NT2) (data not shown). B, Schematic representation of MCAD exon 5 introduced
into the VLCAD minigene. Wild-type (VL362C) and c.362CrT mutant (VL362T) exon 5 with 80 bp of intron 4 and 145 bp of intron 5
replaced VLCAD exon 12 and part of the ﬂanking intronic sequences. Gels show the results from ampliﬁcation of cDNA with minigene-
speciﬁc primers.
exon 5 with the SMN1 ESE and the corresponding non-
functional sequence from SMN2. In addition, we replaced
the MCAD ESE in exon 5 with the known ESE sequences
from the human b-globin (HBB) gene (Entrez Gene acces-
sion number 3043) exon 237 and human BRCA1 exon
18,2,7,29,32 both of which also harbor high-score SF2/ASF
motifs (ﬁg. 3A). The MCAD heptamer could be effectively
replaced by the SMN1heptamer, the BRCA1heptamer, and
HBB exon 2 ESE, but not by the nonfunctional SMN2 hep-
tamer or by a heptamer with the ESE-inactivating BRCA1-
NL mutation.29,30 Exon 5 inclusion was restored from all
constructs when the suboptimal intron 4 3′ splice site was
converted to a strong splice site (ﬁg. 3C), underscoring
that it is this weak 3′ splice site that makes exon 5 depen-
dent on a functional ESE.
Because the nucleotide sequences of the BRCA1 exon
18 and HBB exon 2 ESEs are very different from the MCAD
and SMN1 ESEs (ﬁg. 3A)—reﬂecting the degeneracy of
the consensus sequences—these observations also argue
against changes in RNA secondary structure or introduc-
tion of ESSs as an explanation for exon 5 skipping.
To further investigate whether the SF2/ASF high-score
heptamer motif inMCAD exon 5 represents a genuine ESE,
we tested it in a heterologous context. For this purpose,
we constructed a minigene with exon 18 and part of the
ﬂanking introns of BRCA1 (ﬁg. 3D). Inactivation of the
SF2/ASF–dependent ESE in BRCA1 exon 18 by the BRCA1-
NL mutation (position 6 GrT) or by a 3-bp deletion has
been shown to cause exon skipping in patient cells.30,38
Substitution of the ESE with the SMN1 exon 7 SF2/ASF
heptamer or four other SF2/ASF high-score heptamers
leads to normal splicing in vitro from a BRCA1 minigene,
whereas substitution with the nonfunctional BRCA1-NL
heptamer, the SMN2 heptamer, or two other heptamers
with SF2/ASF scores below threshold leads to exon 18
skipping.2,29 We made four BRCA1 exon 18 minigeneswith
different heptamers at exon 18 positions 4–10 (ﬁg. 3D).
Transfection into Chang cells clearly showed that the
BRCA1-WT minigene had normal exon 18 inclusion,
whereas the BRCA1-NL mutation led to complete exon 18
skipping (ﬁg. 3D). The BRCA1 heptamer could be suc-
cessfully substituted with the wild-type MCAD heptamer,
indicating that the MCAD heptamer can indeed function
as an ESE. Interestingly, substitution with the c.362CrT
MCAD heptamer resulted in some skipping of BRCA1 exon
18 but not to nearly the same extent as that observed with
the BRCA1-NL construct.
If the extent of BRCA1 exon 18 inclusion reﬂects the
ability of the inserted heptamers to bind SF2/ASF, it would
indicate that the c.362CrT MCAD heptamer may still
have some residual afﬁnity for SF2/ASF but not enough
to ensure correct splicing in the context of MCAD exon
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Figure 3. Characterization of the MCAD c.362 ESE. A, An alignment of all the variant sequences, which were inserted around position
c.362 in the MCAD minigene, as well as the relevant part of one of the winner sequences (SF2/ASF-22 [B5]) identiﬁed by functional
systematic evolution of ligands by exponential enrichment (SELEX).48 Mutant positions are underlined. A pictogram for the SF2/ASF
score matrix is shown above the relevant part of the sequence.7 Scores from ESEﬁnder analysis for SF2/ASF, SC35, and SRp40 high-score
motifs are shown to the right. B, A c.363TrG suppressor mutation, which reestablished the SF2/ASF high-score motif when present
with the c.362CrT mutation, introduced into the wild-type and c.362CrT MCAD minigenes. C, We substituted positions c.355-c.364 of
the MCAD sequence in the MCAD minigene with positions 4–12 of exon 7 from the human SMN1 and SMN2 genes, including the SF2/
ASF heptamer motif and the inactive mutant form. Nucleotides corresponding to positions c.355–c.366 of the MCAD sequence were
substituted with positions 1–12 from the human BRCA1 gene exon 18, thereby introducing the SF2/ASF–dependent ESE. The heptamer
with the inactivating BRCA1-NL mutation was also inserted. Nucleotides corresponding to positions c.357–c.368 of MCAD were substituted
with nucleotides 20–32 of HBB exon 2, which has been reported to contain a functional SR protein–dependent ESE.37 The SF2/ASF
high-score heptamer and the three ﬂanking nucleotides from the HBB exon 2 ESE exactly match the winner sequence (SF2/ASF-22
[B5]).48 The SMN1, SMN2, BRCA1-WT, and BRCA1-NL heptamers were also inserted in the MCAD minigene with an optimized intron 4 3′
splice site (IVS). D, Schematic representation showing the BRCA1 exon 18 minigene. We made four BRCA1 exon 18 minigenes with
different heptamers at exon 18 positions 4–10: one with BRCA1-WT, one with the inactivating GrT mutation (BRCA1-NL), one construct
in which the BRCA1 heptamer was replaced by the wild-type MCAD heptamer (BRCA1-MCAD 362C), and one in which the BRCA1 heptamer
was replaced by the c.362CrT mutant MCAD heptamer (BRCA1-MCAD 362T). An alignment of the four different inserted sequences is
shown with the calculated scores for SF2/ASF, SC35, and SRp40 from the ESEﬁnder program.7 The mutations are underlined. E, The wild-
type and c.362CrT mutant MCAD minigenes, as well as the versions with the 3-bp (positions c.361–363) and 9-bp (positions c.358366)
deletions, cotransfected with vectors overexpressing SF2/ASF or SRp40 or with an expression vector without an insert. All the minigenes
were transfected into Chang cells, and cDNA was prepared, was ampliﬁed by minigene-speciﬁc primers, and was analyzed by electrophoresis
in 2% agarose gels.
5. If this assumption is correct, it should be possible to
increaseMCAD exon 5 splicing from the c.362CrTmutant
minigene by increasing the cellular amounts of SF2/ASF.
To test this idea, we performed cotransfection experiments
with our MCAD minigenes and expression vectors encod-
ing SF2/ASF and other SR proteins. Overexpression of SF2/
ASF had a signiﬁcant positive effect on exon 5 inclusion
from the c.362CrT construct (ﬁg. 3E), whereas overex-
pression of SRp40 (ﬁg. 3E) or SRp55, hTra2-b1, and 9G8
(not shown) had only a weak positive effect. SF2/ASF over-
expression did not result in any signiﬁcant exon 5 inclu-
sion from minigenes in which the MCAD ESE had been
deleted or replaced by the SMN2 heptamer or the BRCA1-
NL heptamer (data not shown). These results support the
notion that the c.362CrT mutation reduces but does not
completely abolish the ability of the MCAD ESE to bind
SF2/ASF and that this partial defect may be compensated
for by increasing the cellular concentration of SF2/ASF.
The Negative Effect of the c.362CrT Mutation Is
Antagonized by a Flanking Polymorphic c.351ArC
Synonymous Variation
It has been proposed that inhibitory elements may be pre-
sent in the 5′ end of exon 7 of SMN2, either as an extended
splicing-inhibitory context (“exinct”) from the ﬂanking 3′
splice site to position 12 in exon 721 or as a more localized
sequence in positions 1–6.19 Interestingly, sequence align-
ment shows that the region ﬂanking the MCAD ESE from
positions c.348 to c.362 is nearly identical to the region
that ﬂanks the SMN1 SF2/ASF ESE and is part of the pro-
posed 5′ inhibitory element in SMN2 (ﬁg. 4). This obser-
vation suggests that this region of MCAD exon 5 may also
play a similar role, which is particularly intriguing be-
cause a c.351ArC polymorphic synonymous variation24
is present in this region. Remarkably, introduction of the
c.351ArC variant rescues splicing from the c.362CrT
minigene (ﬁg. 4). This result clearly illustrates that pre-
sumed neutral polymorphic variants may in fact have im-
portant effects on splicing and that the different poly-
morphic allelic context may deﬁne the consequences of
ESE-inactivating or other splicing mutations.
The Polymorphic c.351ArC Variation Inactivates an ESS
The effects of the c.351ArC substitution in the mutant
context could be due to inactivation of an ESS by c.351C
or, vice versa, to inactivation of an additional ESE by
c.351A. To address these alternatives, we generated an-
other panel of mutants (ﬁg. 4), with the substitution of
two of the G nucleotides with C nucleotides (353C354C)
or the deletion of the four G nucleotides (Del352–Del355).
Similar to the c.351C variant, both neutralized the neg-
ative effect of c.362CrT, suggesting that it is the disrup-
tion of an ESS surrounding position c.351 that is respon-
sible for neutralization of the deleterious effect of the
c.362CrT mutation.
However, deletion of only two of four G nucleotides
(Del352 and Del353) did not correct splicing, showing
that the ESS is not compromised when the last two G
nucleotides are replaced by T nucleotides. When the ESE
was disrupted by the 3-bp or the 9-bp deletion or was
replaced by the SMN2 heptamer in constructs in which
the ESS was simultaneously disrupted (353C354C), we
observed normal exon 5 inclusion (ﬁg. 4). These results
strengthen the identiﬁcation of this element as an ESS and
show that its inactivation makes splicing of MCAD exon
5 independent of the c.362C ESE.
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Figure 4. The c.351ArC synonymous polymorphism inactivates
an ESS. Various combinations of mutations were introduced in the
MCAD minigene around positions c.351 and c.362. An alignment
of the sequences from positions 5 in intron 6 to 16 in exon
7 of the SMN2 gene with positions c.348–c.368 from all the MCAD
minigene constructs is shown, with the mutant positions under-
lined. The exinct element21 is boxed. The uppercase letters rep-
resent the exonic sequence, and the lowercase letters represent
the intronic sequences of the SMN2 gene. The functional ESS se-
quence is shaded in gray, and the inactivated ESS is shaded in
black. All minigenes were transfected transiently into Chang cells,
and cDNA was prepared, was ampliﬁed with minigene-speciﬁc prim-
ers, and was analyzed by electrophoresis in 2% agarose gels.
It is noteworthy that when the ESS is disrupted there is
also normal exon 5 inclusion from the MCAD minigene
with the SMN2 heptamer inserted, indicating that the
SMN2 heptamer sequence is not intrinsically inhibitory
as suggested elsewhere18 and conﬁrming the ESE-loss
model.19 The CAG/GGT at the junction of intron 6 and
exon 7 in the SMN1/2 pre-mRNA sequences is very similar
to the CAGGGG ESS sequence in MCAD (ﬁg. 4), and it is
therefore logical to speculate whether it also represents a
splicing silencer and, thus, whether splicing of MCAD
exon 5 and SMN exon 7 is inhibited by a similar mech-
anism, which requires the presence of an antagonizing
ESE for exon inclusion to occur.
We therefore introduced the four variants of the MCAD
sequence from position c.348 to c.366 and the correspond-
ing four variants of the SMN1/2 genes (ﬁg. 5) into exon 2
of a slightly modiﬁed version of the pSXN-splicing re-
porter minigene.31,32,39 This showed that also in this con-
text the MCAD c.351A ESS inhibits splicing and that this
can be antagonized by the c.362C ESE. Inactivation of the
MCAD ESS by c.351ArC improved splicing signiﬁcantly,
and the corresponding ArC substitution in the CAGGGT
sequence from SMN1/2 also had a dramatic positive effect
on splicing, indicating that CAGGGT is also a splicing
silencer. In addition, disruption of the MCAD ESE by
c.362CrT and disruption of the SMN1 ESE by 6CrT
(SMN2) decreased splicing efﬁciency, indicating that splic-
ing efﬁciency is determined by a balance between the ESE
and the splicing silencer in both MCAD and SMN1/2.
When the MCAD ESS sequence in the pSXN minigene was
replaced by either the hexamer sequence of the prototyp-
ical hnRNP A1-binding ESS3 from HIV-1 tat exon 334,40,41
or an inactive mutant form (ﬁg. 5), we observed a similar
splicing pattern as that observed with the MCAD ESS,
showing that in this system the MCAD ESS and a proto-
typical hnRNP A1-binding splicing silencer have similar
effects.
The c.362CrT Mutation and the c.351ArC Polymorphic
Variation Affect Binding of hnRNP A1 to MCAD Exon 5
RNA
Indeed, the MCAD ESS is nearly identical not only to the
potential silencer in SMN but also to a recently identiﬁed
bona ﬁde hnRNP A1-binding ESS in HPV-16 L142 and to
hnRNP A1-binding ESS sequences in b-tropomyosin (b-TM)
exon 6B,43 which all harbor the core sequence CAGGGT
(ﬁg. 6). It is worth noting that hnRNP A1 binding is abol-
ished when the A nucleotide corresponding to c.351A was
changed to C in these ESS sequences.42,43 Moreover, hnRNP
A1-mediated inhibition of SMN exon 7 splicing has been
demonstrated in two independent studies.17,18 On thebasis
of this evidence, we propose that the c.351ArC substi-
tution inactivates the ESS by decreasing its ability to bind
hnRNP A1.
To directly test this hypothesis, we ﬁrst analyzed hnRNP
A1 binding to in vitro–transcribed MCAD exon 5 RNA
samples with all four combinations of c.351A/C and
c.362C/T. Using a pull-down assay, we demonstrated that
inactivation of the MCAD ESS by c.351ArC decreased
hnRNP A1 binding and that inactivation of the MCAD ESE
by c.362CrT resulted in more hnRNP A1 binding (ﬁg. 7A).
Furthermore, substitution of the MCAD ESE with the
SMN1 ESE gave similar results, whereas substitution with
the inactive SMN2 heptamer resulted in increased hnRNP
A1 binding (results not shown).When in vitro–transcribed
MCAD exon 5 RNA samples with the four combinations
of c.351A/C and c.362C/T were investigated in a bandshift
assay with recombinant hnRNP A1 (results not shown),
the results were consistent with those from the pull-down
assay. We could not demonstrate a difference in SF2/ASF
binding between the four combinations of the in vitro–
transcribed MCAD exon 5 RNA. To more speciﬁcally in-
vestigate hnRNP A1 and SF2/ASF binding to the MCAD
ESE and ESS motifs, we performed RNA-afﬁnity chroma-
tography with RNA oligonucleotides harboring only the
different motifs (ﬁg. 7B). This analysis also showed that
c.351ArC drastically decreased hnRNP A1 binding and
conﬁrmed that the MCAD c.362C ESE can bind SF2/ASF,
but again we could not demonstrate a signiﬁcant differ-
ence in SF2/ASF binding between the c.362C and
c.362CrT oligonucleotides, although we could demon-
strate a clear difference in SF2/ASF binding to the SMN1
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Figure 5. Analysis of the CAGGGG/CAGGGT splicing silencer and its interplay with the MCAD and SMN1 ESEs. Different combinations
of the functional (351A) or inactive (351C) MCAD ESS, a prototypical hnRNP A1–binding ESS from HIV-1 tat exon 3 (ESS3A) or an
inactive version (ESS3C), and a wild-type (C5A) or mutant (C5G) sequence from exon 10 of the HC5 gene (see the “Discussion” section)
were tested in combination with the MCAD wild-type (362C) or mutant (362T) ESE in the pSXN reporter minigene. Also, the wild-type
splicing silencer from SMN1/2 (351A) or an inactive version (351C) was tested in combination with either the functional SMN1 ESE or
the corresponding nonfunctional SMN2 heptameric sequence. For easy comparison, an alignment of all the inserted sequences is shown.
The functional splicing-silencer elements are marked as gray boxes with black letters, and inactivated splicing silencers are marked as
black boxes with white letters. All minigenes were transfected transiently into Chang cells, and cDNA was prepared, was ampliﬁed with
minigene-speciﬁc primers, and was analyzed by electrophoresis in 4% agarose gels.
and SMN2 oligonucleotides. This indicates that there is
not a drastic difference between the SF2/ASF-binding af-
ﬁnity of the c.362C and c.362CrT ESEs, and it is consis-
tent with our ﬁndings from our minigene experiments,
which showed that splicing of the MCAD minigene with
the c.362CrT ESEs could be improved by SF2/ASF over-
expression (ﬁg. 3).
Finally, we performed small interfering RNA (siRNA)–
mediated down-regulation of hnRNP A1 and hnRNP A2
in HEK-293 cells and transfected them with the four com-
binations of the MCAD minigene (ﬁg. 7C). This showed
an increased exon 5 inclusion from the c.362CrT con-
struct in which the hnRNP A1-binding c.351A ESS was
present. This indicates that, when hnRNP A1 (and perhaps
also hnRNP A2) is down-regulated by siRNA treatment,
some of the inhibitory effect of the c.351A ESS is allevi-
ated, allowing for improved splicing from the construct
in which the ESE is disrupted by the c.362CrT mutation.
We therefore believe that hnRNP A1 binding to the ESS
in MCAD exon 5 RNA is dependent on the presence of
c.351A or c.351C and that this binding is normally an-
tagonized by the simultaneous presence of a functional
ESE (MCAD c.362C).
Discussion
The present study was initiated to follow up on our ob-
servation that a c.362CrT missense mutation causes a
drastic decrease in the amounts ofMCADmRNA in patient
ﬁbroblasts (ﬁg. 1). Our analyses of patient cDNA and
MCAD minigenes explains this observation, since they
clearly demonstrate that the c.362CrT mutation results
in skipping of MCAD exon 5 during pre-mRNA splicing,
which in turn should lead to degradation of themisspliced
mRNA by NMD.1 The effects observed are thus caused by
missplicing and not by instability of the c.362CrTmutant
mRNA.
At ﬁrst glance, an explanation of how the c.362CrT
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Figure 6. Analysis for high-score motifs for hnRNP A1 binding and identiﬁcation of potential splicing-inhibitory hexamers with the
use of FAS-ESS. A position-weight scoring matrix for hnRNP A1 binding (top) based on the original SELEX winner sequences identiﬁed
by Burd and Dreyfuss53 was recently reported.19 We used the version with background composition correction for the winner pool, to
calculate scores for the known and potential ESS sequences listed. High-score motifs for hnRNP A1 binding are written in black letters,
and the corresponding inactive sequences are written in black boxes with white letters. Mutational changes are underlined. Calculated
high scores are listed in blue, whereas scores !2.7 are listed in red. Potential splicing-inhibitory motifs identiﬁed by analysis of the
sequences with the FAS-ESS program are listed to the right.
mutation can cause exon 5 skipping seems straightfor-
ward, since our results point toward a simple model, ac-
cording to which c.362CrT directly disrupts an SF2/ASF–
dependent ESE, which is necessary for recognition of the
weak 3′ splice site of MCAD intron 4. The fact that we can
abrogate the deleterious effect of the c.362CrT mutation
and all other inactivating mutations when the weak in-
tron 4 3′ splice site is converted to a strong splice site
demonstrates that the ESE is required only when the splice
site is weak. This is consistent with the oldest and best-
documented model for ESE function, in which binding of
SR proteins to an ESE improves U2AF65 recognition of the
weak polypyrimidine tract of an upstream 3′ splice site by
stabilizing its binding through protein-protein interaction
with the RS domain of U2AF.35,44,45
Remarkably, a c.351ArC synonymous polymorphic var-
iation,24 which is also located in exon 5, is able to neu-
tralize the negative effect of the c.362CrT mutation, al-
lowing correct splicing independent of the c.362C ESE.
This shows that the regulation of splicing of MCAD exon
5 is more complex and is determined by interplay between
different regulatory elements, and it points to polymor-
phic variants as powerful effectors of gene-expression
modulation. Our experiments with different combina-
tions of substitutions and deletions in and around posi-
tions c.351 and c.362 in the MCAD minigene (ﬁg. 4) show
that the positive effect of the c.351ArC substitution is
likely due to the disruption of an ESS and not to the cre-
ation of a new ESE, and sequence analysis using the FAS-
ESS program9 further supports this notion (ﬁg. 6).
Because deletion or inactivation of the c.362C ESE does
not affect splicing if the c.351A ESS is simultaneously in-
activated, we speculate that the role of the c.362C ESE
could be mainly to antagonize binding of a repressor to
the c.351A ESS rather than, or in addition to, directly im-
proving recruitment of U2AF to the weak intron 4 3′ splice
site.
Several lines of evidence suggest that the c.351A ESS
functions by binding the splicing repressor hnRNP A1.
First of all, the sequence of this ESS is closely related to
ESS sequences described elsewhere to function by hnRNP
A1 binding in HPV-16 L142 and b-TM exon 6B.43 Second,
analysis of the CAGGGG motif from MCAD exon 5 with
c.351A, by use of a recently reported19 position-weight
scoring matrix for hnRNP A1 binding, gives a high-score
of 3.11, which is reduced to 0.24 by the c.351ArC sub-
stitution (ﬁg. 6). The scores of all the mutant MCAD ESS
sequences tested in the MCAD minigene (ﬁg. 6) are also
consistent with splicing inhibition being mediated by
hnRNP A1 binding (ﬁg. 5). The predictive value of the
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Figure 7. Binding of hnRNP A1 to the MCAD c.351A ESS. A, Afﬁnity chromatography with MCAD exon 5 RNA. Four different in vitro–
transcribed MCAD exon 5 RNAs used for afﬁnity chromatography with HeLa nuclear extract (NE). The proteins bound were analyzed by
SDS-PAGE and western blotting with the use of an hRNP A1 antibody or an SF2/ASF antibody. The in vitro–transcribed MCAD exon 5
RNA harbored either the functional ESS (351A) or the inactivated ESS (351C), in combination with either wild-type (362C) or ESE (362T)
sequence. B, RNA oligonucleotide-afﬁnity chromatography. The sequences of the six different RNA oligonucleotides that were used for
afﬁnity chromatography in HeLa NE are shown. The bound proteins were analyzed by western blotting with the use of hnRNP A1 and
SF2/ASF antibodies. C, RNA interference. For RNA interference, either double-stranded RNA oligonucleotides directed toward hnRNP A1
and hnRNP A2 (A1A2) or a negative control were transfected into HEK-293 cells. The effect on splicing from four different MCAD
minigenes was monitored by ampliﬁcation of cDNA with minigene-speciﬁc primers. Transfections were done in triplicate, and the gel
shows the results from one representative experiment. hnRNP A1 down-regulation was monitored by western blotting with the use of
hnRNP A1 and hnRNP A2/B1 antibodies (not shown).
hnRNP A1-binding matrix is substantiated by the ﬁnding
that the scores from the mutant motifs of the HPV-16 L1
ESS and the b-TM exon 6B ESS, which have been dem-
onstrated to abolish hnRNP A1 binding,42,43 are dramati-
cally lower than those of the corresponding wild-type ESS
sequences (ﬁg. 6). The scores of the tested hexamer from
the prototypical hnRNP A1-binding ESS3 from HIV-1 tat
exon 334,40,41 or an inactive mutant form (ﬁg. 6) also sub-
stantiated the predictive value of the hnRNP A1 scoring
matrix. Moreover, in vitro hnRNP A1-binding studies (ﬁg.
7) showed that MCAD exon 5 RNA and an RNA oligo-
nucleotide with the c.351A ESS both have a higher level
of hnRNP A1 binding than do the c.351C variants. Finally,
hnRNP A1/A2 down-regulation by siRNA leads to in-
creased exon 5 inclusion from the minigene with the
c.351A ESS (ﬁg. 7).
We therefore conclude that the MCAD c.351A ESS may
inhibit splicing by binding of hnRNP A1. The in vitro
binding studies also indicated that the c.362C ESE antag-
onizes hnRNP A1 binding to exon 5 RNA, and, when the
strength of the c.362C ESE was decreased by the c.362CrT
mutation, there was stronger hnRNP A1 binding. Fur-
thermore, the SMN1 ESE, but not the inactive SMN2 hep-
tamer, could also antagonize hnRNP A1 binding to MCAD
exon 5 RNA in vitro (results not shown). These results
strongly suggest that the role of the c.362C ESE is not
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primarily to directly assist in U2AF recruitment to the
weak 3′ splice site but, instead, to antagonize hnRNP A1
binding to the c.351A ESS, a mode of function of ESE
elements observed elsewhere for regulation of the IgM
gene.46 Alternatively, the c.362C ESE could antagonize
hnRNP A1 propagation from the c.351A ESS in a manner
similar to what has been proposed in HIV-1 tat exon 3,
where SF2/ASF binding to a ﬂanking ESE blocks the 3′ to
5′ propagation by hnRNP A1 from its high-afﬁnity binding
site in ESS3.41 Splicing regulation by a balance between
the competing effects of SF2/ASF and hnRNP A1 is known
also from other genes.43,47
Many of our results suggest that the MCAD c.362C ESE
functions by SF2/ASF binding. Analysis with the ESEﬁnder
program shows that c.362CrT decreases the score of the
SF2/ASF motif below the threshold of 1.956 (ﬁg. 3), and
restoration of the SF2/ASF high-score motif by a compen-
satory mutation (c.363TrG) restored splicing from the
c.362CrT MCAD minigene. In the MCAD minigene, the
c.362C ESE can be substituted by the SF2/ASF high-score
ESE sequences from BRCA1 exon 18, SMN1 exon 7, and
HBB exon 2 but not by their inactive mutant forms. This
observation shows that different sequences with SF2/ASF
high-score motifs can counteract the function of the
c.351A ESS and, consequently, that the antagonizingeffect
is mediated through protein binding to the ESE and not
by changes in RNA secondary structure. The SMN1 and
BRCA1 ESE heptamers have both been demonstrated to
function by SF2/ASF binding,2,19,29 and the HBB exon 2
ESE has a high-score SF2/ASF motif that exactly matches
that of a functionally tested SF2/ASF–binding motif (ﬁg.
3A).48 When the c.362C ESE was tested in a heterologous
context, it was able to substitute for the natural ESE in
BRCA1 exon 18. All these results show that an SF2/ASF–
dependent ESE positioned around c.362 in MCAD exon 5
is sufﬁcient to ensure correct splicing, but we cannot ex-
clude the possibility that the c.362C ESE normally func-
tions by the binding of another splicing factor with over-
lapping function and RNA-binding speciﬁcity similar to
that of SF2/ASF. The fact that we are unable to demonstrate
differences in SF2/ASF binding in our in vitro binding
studies may speak in favor of this latter possibility, but it
may also simply reﬂect the fact that even subtle changes
in binding afﬁnity, which are not detectable by our in vitro
approaches, may have drastic effects in vivo. However, we
found that overexpression of SF2/ASF could rescue splic-
ing from the MCAD minigene with the c.362CrT muta-
tion but not from the constructs where the ESEwas deleted
or replaced by the nonfunctional SMN2 or BRCA1-NL se-
quences. This ﬁnding indicates that the c.362CrT mutant
ESE is still able to bind SF2/ASF, but with lower afﬁnity
than the c.362C ESE, and that this can be compensated
for by increasing the cellular concentration of SF2/ASF by
overexpression.
Thus, we propose that the c.362CrT mutationdecreases
the ability of the MCAD ESE to bind SF2/ASF or another
splicing factor with a similar binding motif and function,
so that hnRNP A1 binding to the ﬂanking ESS in MCAD
exon 5 is not antagonized. Interestingly, in the context of
the BRCA1 minigene, the mutant c.362CrT ESE still has
enough strength to partly substitute for an SF2/ASF–bind-
ing ESE, probably because there is no competition from a
ﬂanking ESS. When the MCAD ESE was tested in another
heterologous context—namely, the pSXN system—it was
also obvious that the deleterious effect of c.362CrT is
highly dependent on the presence or absence of a ﬂanking
ESS (ﬁg. 5). This was particularly evident when the MCAD
ESS was substituted by the prototypical hnRNP A1–bind-
ing hexamer from the HIV-1 tat exon 3 ESS. These results
underscore the fact that splicing regulation is determined
by a ﬁnely tuned balance between positive and negative
regulatory elements and, thus, that the effect of a muta-
tion in one element can be highly dependent on the pres-
ence or absence of other elements in the same allele.
The precise mechanism by which hnRNP A1 binding to
the MCAD c.351A ESS is able to repress splicing is not clear.
One mechanism, which was originally suggested to ex-
plain HIV-1 tat exon 3 splicing,41 could be that hnRNP A1
binding to the c.351A ESS facilitates cooperative binding
of hnRNP A1 to other sites in exon 5 or the ﬂanking in-
trons and that hnRNP A1 complex formation along the
RNA masks essential splicing determinants, such as the
splice sites or ESEs that are necessary for recognition of
the weak 3′ splice site in intron 4. Another mechanism,
initially proposed by Chabot and coworkers,49,50 could be
that hnRNP A1 bound to the c.351A ESS forms a dimer
with hnRNP A1 bound to another silencer and thereby
causes looping out of the RNA and masking of one or both
splice sites. In this case, the second hnRNP A1–binding
site must likely be located in the part of MCAD that was
subcloned into the VLCAD minigene, since exon 5 skip-
ping was also observed in that context. Examination of
the subcloned sequence with the hnRNP A1 scoring ma-
trix identiﬁed several additional high-score motifs in
MCAD (data not shown).
It seems likely that the nearly identical SMN1/2 splicing
silencer (CAGGGT) that we have identiﬁed also functions
by binding of hnRNP A1. It was noted elsewhere19 that
this CAGGGT sequence that overlaps the weak 3′ splice
site at the intron 6–exon 7 junction of SMN1/2 gives a
high score with the hnRNP A1 matrix. When we tested
this motif and the inactive CCGGGT version in the pSXN
system, we observed (ﬁg. 5) that, similar to the MCAD
c.351A ESS, it functions as a splicing silencer, which can
be inactivated by the ArC mutation.Moreover, it has been
shown that splicing of SMN1/2 exon 7 is inhibited by
hnRNP A1 and that splicing of exon 7 from SMN2 can be
activated by in vivo depletion of hnRNP A1/A2 by RNA
interference.18,19 On the basis of these ﬁndings, we suggest
that the CAGGGT high-score hnRNP A1 motif at the
SMN1/2 intron 6–exon 7 junction is a splicing silencer that
can bind hnRNP A1. If this is correct, hnRNP A1 may
inhibit SMN1/2 exon 7 splicing by binding to this silencer
and thereby directly inhibit U2AF35 binding. It is likely
Figure 8. Models for splicing regulation of MCAD exon 5 (A–D), SMN1/2 exon 7 (E and F), and HC5 exon 10 (G and H). A–D, MCAD
exon 5. The weak intron 4 3′ splice site is inefﬁciently recognized by U2AF, and its recognition is probably dependent on assembly of
stimulatory complexes on an ESE in exon 5. One possibility is that the purine-rich motif (ESE2?), which is nearly identical to the hTra2-
b1–binding ESE2 in SMN exon 7, assists in recognition of the weak intron 4 3′ splice site in this way. Binding of hnRNP A1 to the ESS
(351A) inhibits recognition of the weak 3′ splice site, probably by antagonizing the stimulatory effect of splicing-enhancer elements
(like ESE2?) and/or more directly by functioning as a primary hnRNP A1-binding site, which stimulates binding of further hnRNP A1
molecules in a way that may directly mask the weak 3′ splice site and/or antagonize the function of crucial ESEs (like ESE2?). The
primary function of ESE1, which comprises position c.362, is to antagonize binding of hnRNP A1 to the ESS. The c.362CrT mutation
decreases the strength of ESE1, so that hnRNP A1 binding to the ﬂanking ESS is favored. ESE1 is necessary for correct splicing only
when the ESS (351A) is functional. In alleles with c.351C, the ESS is not functional, and ESE1 is therefore not required to inhibit
hnRNP A1 binding. The ESE1 may function by binding SF2/ASF (as depicted in the ﬁgure) or another splicing factor with similar
recognition motif and function. E and F, SMN1 and SMN2 exon 7. Recognition of exon 7 is dependent on ESE1 and ESE2 for recognition
of the weak intron 6 3′ splice site. Binding of hTra2b1 to ESE2 recruits SRp30c and hnRNPG, and this complex assists, perhaps via
interactions of the RS domains of hTra2b1/SRp30c and U2AF,35 in recognition of the 3′ splice site. An hnRNP A1–binding motif (CAGGGT),
which can function as a splicing silencer, overlaps with the 3′ splice site, and it is likely that U2AF and hnRNP A1 compete for binding
at this site. In SMN1, binding of SF2/ASF to ESE1 antagonizes binding of hnRNP A1 to the splicing silencer, thereby allowing U2AF
binding and exon 7 inclusion. In addition to counteracting hnRNP A1 binding to the splicing silencer, it is also possible that the RS
domain of bound SF2/ASF participates in U2AF recruitment. In SMN2 the 6CrT substitution in ESE1 allows binding of hnRNP A1 to
the splicing silencer. U2AF binding is thus antagonized, and exon 7 is skipped. G and H, HC5 exon 10. An ArG mutation at the
penultimate position of exon 10 has been shown to cause exon 10 skipping.13 This ArG mutation generates an hnRNP A1–binding site
(CAGGGT) identical to the splicing silencer in SMN1/2. Binding of hnRNP A1 at the 5’ splice site would block access by U1 snRNP and
result in skipping of the exon. Exonic sequences are represented by uppercase letters (boxed) and intronic sequences by lowercase
letters. Blue letters represent the SF2/ASF (blue) recognition sequence (ESE1), green letters the hTra2b1 (green) binding motif (ESE2),
and red letters the hnRNP A1 (red) recognition sequence (ESS). U2AF dimer (yellow) and U1snRNP (purple) are shown.
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that binding of SF2/ASF to the ﬂanking SMN1 ESE pri-
marily functions by antagonizing hnRNP A1 binding to
this silencer. In SMN2, the lack of the ESE prevents this
SF2/ASF function and leads to exon 7 skipping. Such a
mechanism is consistent with our in vitro binding studies,
in which the SMN1 ESE, just like the MCAD c.362C ESE,
antagonizes binding of hnRNP A1 to MCAD exon 5 RNA
with the c.351A ESS (ﬁg. 8). Moreover, using the pSXN
system, we could demonstrate that interplay between the
CAGGGT high-score hnRNP A1 motif and the SMN1 ESE
determines exon inclusion in this heterologous context,
just as with the MCAD ESE and ESS (ﬁg. 5).
Recently, the creation of a CAGGGT motif by an exon-
skipping mutation in the HC5 gene was reported.13 In this
case, a mutation from CAAGGT to CAGGGT causes exon
10 skipping, and it was proposed that this is due to loss
of an ESE motif (ATCAAG), which is predicted by the RES-
CUE-ESE program. However, the hnRNP A1 matrix score
of the CAGGGT sequence is dramatically higher than that
of the CAAGGT sequences (ﬁg. 6). When we substituted
the MCAD c.351A ESS sequence in the pSXN minigenes
with either of the two motifs from HC5 exon 10, the re-
sults corroborated that this ArG mutation creates a splic-
ing silencer (ﬁg. 5). This high-score hnRNP A1 motif over-
laps with the weak 5′ splice site of HC5 exon 10, and it is
therefore possible that hnRNP A1 binding to the mutant
sequence directly competes with U1 snRNP binding to the
5′ splice site and thereby contributes to HC5 exon 10
skipping.
On the basis of all these results, we have summarized
in ﬁgure 8 some simple models to explain how the reg-
ulatory elements that we have studied may function in
splicing regulation of MCAD exon 5, SMN1/2 exon 7, and
HC5 exon 10. These examples nicely illustrate why pre-
diction of the possible effect of exonic point mutations
on splicing is not a simple matter. The in silico predictions
of putative ESEs and ESSs by available computer programs
can suggest possible effects, but these are not necessarily
correct, and different programs may give apparently con-
ﬂicting predictions (i.e., “ESE-loss” vs. “ESS-gain”), as ex-
empliﬁed by the ArG mutation in HC5 exon 10. More
importantly, our results emphasize that changes in ESE or
ESS elements are relevant only if these elements are re-
quired for exon deﬁnition in a particular context. As il-
lustrated in the present study, the weak 3′ splice site in
MCAD intron 4 is a fundamental prerequisite for an effect
of mutations in exon 5, since strengthening of the poly-
pyrimidine tract makes exon 5 inclusion immune to all
tested exonic mutations. Similarly, it was shown elsewhere
that improvement of the intron 6 3′ splice site leads to
complete exon 7 inclusion from SMN2.19 It is thus rea-
sonable to postulate that only mutations that affect pre-
dicted splicing regulatory elements in weakly deﬁned ex-
ons are likely to have an effect. It is, however, crucial to
keep in mind that exon deﬁnition is governed by multiple
factors. Not only is the strength of the splice sites impor-
tant, but the presence or absence of other regulatory el-
ements located in cis may also be determinative for exon
deﬁnition and correct splicing.2,46,51,52 Despite thepresence
of a weak intron 4 3′ splice site in all MCAD alleles, only
alleles with a functional c.351A ESS are vulnerable to mu-
tations in the c.362 ESE. Thus, the present study illustrates
that it is essential that potential deleterious effects of point
mutations on splicing be evaluated in the context of the
relevant haplotype.
In conclusion, we report a novel mechanism by which
a presumed neutral polymorphic variant (c.351C) in an
exon can protect against disease-causing splicing muta-
tions. This could be a common mode by which SNPs im-
pact gene expression, but, under normal conditions, such
occurrences would be underestimated because the in-
volved ESS elements will be unmasked only when a mu-
tation in cis inactivates the antagonizing ESE element.
This mechanism may also play an important role in
evolution, since substitutions that inactivate such ESS el-
ements would neutralize the restrictions put on splicing-
inactivating mutations elsewhere in the exon.
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